Paul Shapiro, PhD, and Jeffrey Hasday, MD, are developing a class of drugs that may be able to reset the natural balance of inflammation and prevent a number of serious diseases.

New study sheds light on how disease progression and biomolecular corona affect nanoparticle-mediated immune activation.

Researchers and community members attend interactive training sessions together to discuss health care research and patient-centered outcomes